tiprankstipranks
CV Sciences (GB:0HRT)
OTHER OTC:0HRT

CV Sciences (0HRT) Price & Analysis

0 Followers

0HRT Stock Chart & Stats

$0.05
$0.00(0.00%)
At close: 4:00 PM EST
$0.05
$0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Margin ExpansionSustained gross margin improvement reflects lower product costs and partial insourcing, increasing operating leverage. Higher margins help the firm absorb top-line volatility, support path to profitability and reduce reliance on external financing, improving durable cash flow prospects.
Improving Cash-Flow TrajectoryThe shift to positive operating cash flow and management guidance toward break‑even are structural: cost cuts, insourcing and synergies aim to convert improved EBITDA into sustainable cash generation, lowering financing risk and enabling reinvestment without recurring capital raises.
Strategic M&A And InsourcingTargeted bolt-on M&A and bringing manufacturing in-house expand product capabilities, diversify revenue mix and improve supply-chain control. These structural moves can deliver durable cost synergies, margin support and faster new-product commercialization.
Bears Say
Top-line DeclineSustained sales and unit-volume declines signal persistent category weakness or loss of share. Continued top-line erosion undermines fixed-cost absorption, constrains scale economics and forces reliance on margin improvement or further cost cuts to achieve durable profitability.
Negative Cash Flow & Tight LiquidityOngoing negative operating and free cash flow, coupled with a very small absolute cash balance and modest equity cushion, create structural financing risk. Limited liquidity reduces runway for marketing, R&D or execution of growth initiatives without additional capital or dilution.
Regulatory UncertaintyUnclear or shifting federal/state rules for hemp/CBD pose a durable constraint: potential reformulation, restricted channels or compliance costs can shrink addressable markets, slow adoption in institutional channels and raise ongoing product development and legal expenses.

CV Sciences News

0HRT FAQ

What was CV Sciences’s price range in the past 12 months?
CV Sciences lowest share price was $0.03 and its highest was $0.05 in the past 12 months.
    What is CV Sciences’s market cap?
    CV Sciences’s market cap is $3.47M.
      When is CV Sciences’s upcoming earnings report date?
      CV Sciences’s upcoming earnings report date is Aug 17, 2026 which is in 60 days.
        How were CV Sciences’s earnings last quarter?
        CV Sciences released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
          Is CV Sciences overvalued?
          According to Wall Street analysts CV Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CV Sciences pay dividends?
            CV Sciences does not currently pay dividends.
            What is CV Sciences’s EPS estimate?
            CV Sciences’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does CV Sciences have?
            CV Sciences has 203,977,520 shares outstanding.
              What happened to CV Sciences’s price movement after its last earnings report?
              CV Sciences reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of CV Sciences?
                Currently, no hedge funds are holding shares in GB:0HRT
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  CV Sciences

                  CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

                  CV Sciences (0HRT) Earnings & Revenues

                  0HRT Earnings Call

                  Q1 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.View all GB:0HRT earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  cbdMD
                  Cosmos Holdings
                  IM Cannabis Corp
                  Incannex Healthcare Limited Sponsored ADR

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks